cell and gene therapies

News

Merck builds in cell, gene therapies with Mirus Bio deal

Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at a

Patients

Conference report: Reuters Pharma Europe

In this special edition of the pharmaphorum podcast, the tables have turned as Jonah Comstock puts edito

Market Access

How manufacturing keeps pace with innovation in cell and gen...

Cell and gene therapies are one of the most fast-moving and paradigm-shifting areas in pharmaceutical development today, bringing curative treatments to patients for the first time for cert

Market Access

Six takeaways from JP Morgan 2024

With another JP Morgan in the rearview mirror, it’s time to take stock of the announcements, the presentations, and, above all, the vibes.

News

Bayer adds a new life science incubator in China

Bayer’s network of Co.Lab life sciences incubators has expanded once again with the announcement of a new site in Shanghai, China, that will focus on oncology cell and gen

R&D

A World Without Disease – AstraZeneca and the Health Works I...

Ahead of the inaugural World Without Disease Summit on Wednesday 21st June, pharmaphorum spoke with the event’s two speakers from AstraZeneca, Stefan Woxström, SVP Europe and Canada, and Stefan Vlachos, Head of Health Works